EPO invalidates Pacific Biosciences patent in Oxford Nanopore dispute

The European Patent Office (EPO) has revoked a patent held by a US biotechnology company, Pacific Biosciences, after its UK-based rival Oxford Nanopore Technologies challenged the validity of the patent.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Pacific Biosciences and Oxford Nanopore settle patent claims

9 May 2018 US-based Pacific Biosciences has entered into a five-year settlement agreement with Oxford Nanopore after the companies were locked in a legal battle.

Big Pharma

Oxford Nanopore secures Fed Circ victory in PacBio DNA suit

13 May 2021 The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid.

More on this story

Americas

Pacific Biosciences and Oxford Nanopore settle patent claims

9 May 2018 US-based Pacific Biosciences has entered into a five-year settlement agreement with Oxford Nanopore after the companies were locked in a legal battle.

Big Pharma

Oxford Nanopore secures Fed Circ victory in PacBio DNA suit

More on this story

Americas

Pacific Biosciences and Oxford Nanopore settle patent claims

9 May 2018 US-based Pacific Biosciences has entered into a five-year settlement agreement with Oxford Nanopore after the companies were locked in a legal battle.

Big Pharma

Oxford Nanopore secures Fed Circ victory in PacBio DNA suit